Bioavailability of Prochlorperazine Suppositories, 25 mg

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00992472

Enrollment

Registered

2009-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this study is to compare prochlorperazine plasma concentrations produced after administration of the test formulation with those produced after administration of a marketed reference product.

Interventions

DRUGProchlorperazine suppositories, 25mg

DRUGCompazine® suppositories, 25mg

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening

Exclusion criteria

* Positive test results for HIV or Hepatitis B or C * History of allergy or sensitivity to Prochlorperazine or related drugs

Design outcomes

Primary

Measure	Time frame
Bioequivalence according to US FDA guidelines	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026